
DBV Technologies (DBVT) announced that new data from the Phase 3 VITESSE clinical trial of the VIASKIN Peanut Patch in peanut-allergic children aged 4 to 7 years were highlighted in
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| DBVT | DBV Technologies SA - American | 9.02 | -4.73 | -34.40% |
| Name | Price | % Change | |
|---|---|---|---|
| $9.02 | -34.40% |

DBV Technologies (DBVT) announced that new data from the Phase 3 VITESSE clinical trial of the VIASKIN Peanut Patch in peanut-allergic children aged 4 to 7 years were highlighted in

DBV Technologies S.A. – American Depositary Shares (($DBVT)) has held its Q3 earnings call. Read on for the main highlights of the call. DBV Technologies struck an upbeat tone on

Guggenheim lowered the firm’s price target on DBV Technologies (DBVT) to $46 from $51 and keeps a Buy rating on the shares to reflect a “modest delay” in the BLA

DBV Technologies S.A. – American Depositary Shares (DBVT) has disclosed a new risk, in the Debt & Financing category. DBV Technologies S.A. – American Depositary Shares faces significant going-concern risk,

Analyst Andrew Fein from H.C. Wainwright reiterated a Buy rating on DBV Technologies SA – American and keeping the price target at $40.00. Andrew Fein has given his Buy rating

Shares of DBV Technologies (DBVT) are sinking after the company said “substantial doubt exists” about its ability to continue as a good concern. In last night’s earnings release, DBV commented:

Citizens lowered the firm’s price target on DBV Technologies (DBVT) to $47 from $55 and keeps an Outperform rating on the shares. DBV’s Viaskin Peanut BLA for ages 4-7 could

“The third quarter marked a defining step in DBV’s evolution from a clinical-stage company into a commercial organization. With our BLA now submitted for children aged 4 through 7 years,

DBV Technologies S.A. – American Depositary Shares (DBVT) is scheduled to report 3rd quarter earnings on 10/28/2026, after the market closes. Regarding Q3 estimates, Wall Street analysts expect DBV Technologies

LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on DBVT stock, giving a Buy rating on September 21. Sam Slutsky has given his Buy rating due to a
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 11, 2027TBA | $571.85M | $-0.21 | $625.00K | -0.27 | -3.03 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.